Abstract

It was reported that the main chemical constituents in plants of genus Peganum were a serial ofβ-carboline and quinoline alkaloids. These alkaloids were quantitatively assessed for selective inhibitory activities on acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) byin vitroEllman method. The results indicated that harmane was the most potent selective AChE inhibitor with an IC50of 7.11 ± 2.00 μM and AChE selectivity index (SI, IC50of BChE/IC50of AChE) of 10.82. Vasicine was the most potent BChE inhibitor with feature of dual AChE/BChE inhibitory activity, with an IC50versus AChE/BChE of 13.68 ± 1.25/2.60 ± 1.47 μM and AChE SI of 0.19. By analyzing and comparing the IC50and SI of those chemicals, it was indicated that theβ-carboline alkaloids displayed more potent AChE inhibition but less BChE inhibition than quinoline alkaloids. The substituent at the C7 position of theβ-carboline alkaloids and C3 and C9 positions of quinoline alkaloids played a critical role in AChE or BChE inhibition. The potent inhibition suggested that those alkaloids may be used as candidates for treatment of Alzheimer’s disease. The analysis of the quantitative structure-activity relationship of those compounds investigated might provide guidance for the design and synthesis of AChE and BChE inhibitors.

Highlights

  • Alzheimer’s disease (AD) was characterized by dementia that typically begins with subtle recognition failure and poor memory

  • Results from previous studies showed that the alkaloids fraction containing mainly β-carboline and quinoline alkaloids from the seeds of P. nigellastrum exhibited potential inhibitive activity on AchE [14]

  • The inhibitory activities of those individual β-carboline and quinoline alkaloids separated from genus Peganum on AChE and BChE were determined using the in vitro Ellman method

Read more

Summary

Introduction

Alzheimer’s disease (AD) was characterized by dementia that typically begins with subtle recognition failure and poor memory. Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) are hydrolytic enzymes that act on acetylcholine (ACh) to terminate its actions in the synaptic cleft by cleaving the neurotransmitter to choline and acetate. Both enzymes are present in the brain and detected in neurofibrillary tangles and neuritic plaques. BChE activity progressively increases in patients with AD, while AChE activity remains unchanged or declines. Both enzymes represent legitimate therapeutic targets for ameliorating the cholinergic deficit considered to be responsible for the declines in cognitive, behavioral, and global functioning characteristics of AD [3].

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call